ILY101

Phase 2Small molecule

IIlypsa

ILY101 is one of 22 small molecule programs targeting Hyperphosphatemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperphosphatemiaActive, not recruiting

HyperphosphatemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

30 competitors in Hyperphosphatemia

#DrugCompanyPhaseTrials

Niacor

AbbVie

Approved

2 2

Fosrenol

Takeda

Approved

1 3

Renvela

Sanofi

Phase 3

5 4

Tums

Otsuka

Phase 3

3 5

Sevelamer Hcl

Novartis

Approved

1 6

Ibsrela

AArdelyx

Phase 3

3 7

Calcium-Based Phosphate Binder

Sanofi

Approved

1 8

Cholestyramine Resin

SSeoul National University Hospital

Approved

1 9

Nicotinic Acids

HHeidelberg University

Approved

1 10

MCI-196

Tanabe Pharma Corporation

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hyperphosphatemia1 trial

Efficacy and Tolerability of ILY101 in Dialysis Patients With Hyperphosphatemia

Unknown status·IIlypsa·Phase 2·NCT00358046·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ILY101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ILY101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ILY101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ilypsa company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IIlypsa

ILY101

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hyperphosphatemia1 trial

References

Drug Info

Quick Facts

Related News